Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

Publisher： Karger

E-ISSN： 2296-5262|39|1-2|18-24

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.1-2, 2016-0, pp. : 18-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 365-371

Karger

Access to resources Recommend Favorite

Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3869-3876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 103-104

Karger

Access to resources Recommend Favorite

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 446-460

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab for the treatment of chronic lymphocytic leukemia

By Robak Tadeusz  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 577-587

Future Medicine

Access to resources Recommend Favorite